Biotech | April 13, 2022
Switzerland grants conditional marketing authorisation for Novavax Covid-19 vaccine
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
High level of vaccine efficacy maintained over a 6-month period of surveillance
The first wave of shipments includes several countries, such as Germany, France and Austria
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied. Vaccine was well-tolerated with no safety signals identified
It would be the first protein-based alternative available in Israel
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
Subscribe To Our Newsletter & Stay Updated
